Can I read Bone Marrow Effects of Anagrelide Therapy in Patients with Myelofibrosis with Myeloid Metaplasia on EtoBox?

Bone Marrow Effects of Anagrelide Therapy in Patients with Myelofibrosis with Myeloid Metaplasia by Soo-Young Yoon; Chin-Yang Li; Ruben A. Mesa; Ayalew Tefferi is a Medicine article available to read on EtoBox.

What is Bone Marrow Effects of Anagrelide Therapy in Patients with Myelofibrosis with Myeloid Metaplasia about?

In a prospective study investigating the therapeutic role of anagrelide in myelofibrosis with myeloid metaplasia, 20 patients received anagrelide in daily oral doses of 0.5–3 mg. 17 patients were evaluable and received anagrelide for a median of 2 years (range 0.5–4 years). No patient had a clinically appreciable benefit. Bone marrow (BM) examinations at baseline and after 6 and 12 months of treatment were available for 17, 17 and 12 patients, respectively. In all evaluable cases, BM megakaryocyte number increased after 6 months of anagrelide treatment. Also, __Ulex europaeus__ agglutinin‐1 staining of megakaryocytes revealed a left‐shifted maturation pattern in most patients with a platelet response to anagrelide. However, megakaryocyte staining intensity for transforming (TGF‐β) and platelet‐derived (PDGF) growth factors was not affected consistently by treatment. No patient had a 2 grade change in either BM fibrosis or osteosclerosis. These __in‐vivo__ data support our previous __in‐vitro__ observations that anagrelide interferes with megakaryocyte maturation rather than proliferation. Lack of a positive treatment effect is consistent with the finding that anagrelide did not sig

Who reads Bone Marrow Effects of Anagrelide Therapy in Patients with Myelofibrosis with Myeloid Metaplasia?

Author

Soo-Young Yoon; Chin-Yang Li; Ruben A. Mesa; Ayalew Tefferi

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0007-1048)

Published

1999

Language

EN

Field

Medicine (Health Sciences)